• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多种神经氨酸酶包含的流感病毒样颗粒疫苗可保护小鼠免受禽源和人流感病毒感染。

Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.

机构信息

Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea.

Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Korea.

出版信息

Viruses. 2022 Feb 18;14(2):429. doi: 10.3390/v14020429.

DOI:10.3390/v14020429
PMID:35216022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8875606/
Abstract

Avian influenza virus remains a threat for humans, and vaccines preventing both avian and human influenza virus infections are needed. Since virus-like particles (VLPs) expressing single neuraminidase (NA) subtype elicited limited heterosubtypic protection, VLPs expressing multiple NA subtypes would enhance the extent of heterosubtypic immunity. Here, we generated avian influenza VLP vaccines displaying H5 hemagglutinin (HA) antigen with or without avian NA subtypes (N1, N6, N8) in different combinations. BALB/c mice were intramuscularly immunized with the VLPs to evaluate the resulting homologous and heterosubtypic immunity upon challenge infections with the avian and human influenza viruses (A/H5N1, A/H3N2, A/H1N1). VLPs expressing H5 alone conferred homologous protection but not heterosubtypic protection, whereas VLPs co-expressing H5 and NA subtypes elicited both homologous and heterosubtypic protection against human influenza viruses in mice. We observed that VLP induced neuraminidase inhibitory activities (NAI), virus-neutralizing activity, and virus-specific antibody (IgG, IgA) responses were strongly correlated with the number of different NA subtype expressions on the VLPs. VLPs expressing all 3 NA subtypes resulted in the highest protection, indicated by the lowest lung titer, negligible body weight changes, and survival in immunized mice. These results suggest that expressing multiple neuraminidases in avian HA VLPs is a promising approach for developing a universal influenza A vaccine against avian and human influenza virus infections.

摘要

禽流感病毒仍然对人类构成威胁,因此需要预防禽流感和人流感病毒感染的疫苗。由于表达单一神经氨酸酶(NA)亚型的病毒样颗粒(VLPs)引发的异源保护作用有限,因此表达多种 NA 亚型的 VLPs将增强异源免疫的程度。在这里,我们生成了表达 H5 血凝素(HA)抗原的禽流感 VLP 疫苗,其中包含或不包含不同组合的禽 NA 亚型(N1、N6、N8)。用 VLPs 通过肌肉内免疫 BALB/c 小鼠,以评估在挑战感染禽流感和人流感病毒(A/H5N1、A/H3N2、A/H1N1)时产生的同源和异源免疫。单独表达 H5 的 VLPs赋予了同源保护作用,但没有异源保护作用,而共表达 H5 和 NA 亚型的 VLPs在小鼠中引发了针对人流感病毒的同源和异源保护作用。我们观察到,VLP 诱导的神经氨酸酶抑制活性(NAI)、病毒中和活性和病毒特异性抗体(IgG、IgA)反应与 VLPs 上不同 NA 亚型表达的数量强烈相关。表达所有 3 种 NA 亚型的 VLPs 导致最高的保护作用,表现为肺部滴度最低、体重变化可忽略不计以及免疫小鼠的存活率。这些结果表明,在禽 HA VLPs 中表达多种神经氨酸酶是开发针对禽流感和人流感病毒感染的通用流感 A 疫苗的有前途的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/9e041ffc2836/viruses-14-00429-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/1188c82123e6/viruses-14-00429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/843f4a83f3f5/viruses-14-00429-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/162552fa990d/viruses-14-00429-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/230aa08209ce/viruses-14-00429-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/51da5c84b827/viruses-14-00429-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/0f16cf667a36/viruses-14-00429-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/34d07b73f3f5/viruses-14-00429-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/9e041ffc2836/viruses-14-00429-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/1188c82123e6/viruses-14-00429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/843f4a83f3f5/viruses-14-00429-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/162552fa990d/viruses-14-00429-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/230aa08209ce/viruses-14-00429-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/51da5c84b827/viruses-14-00429-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/0f16cf667a36/viruses-14-00429-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/34d07b73f3f5/viruses-14-00429-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd45/8875606/9e041ffc2836/viruses-14-00429-g008.jpg

相似文献

1
Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.多种神经氨酸酶包含的流感病毒样颗粒疫苗可保护小鼠免受禽源和人流感病毒感染。
Viruses. 2022 Feb 18;14(2):429. doi: 10.3390/v14020429.
2
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.含神经氨酸酶的 M1 流感 VLPs 诱导异源型交叉保护。
Virology. 2012 Sep 1;430(2):127-35. doi: 10.1016/j.virol.2012.05.006. Epub 2012 Jun 2.
3
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.一种 VLP 疫苗可诱导针对 H5N1 和 H1N1 亚型流感病毒的广谱交叉保护抗体免疫。
PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.
4
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.接种表达神经氨酸酶的重组副流感病毒5可抵御同源和异源流感病毒攻击。
J Virol. 2017 Nov 14;91(23). doi: 10.1128/JVI.01579-17. Print 2017 Dec 1.
5
Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.2009 年大流行的 H1N1 病毒样颗粒诱导的疫苗效力与裂解流感病毒诱导的不同。
Immunol Invest. 2020 Oct;49(7):781-793. doi: 10.1080/08820139.2019.1694539. Epub 2019 Nov 27.
6
Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.基于神经氨酸酶的重组病毒样颗粒可保护雪貂免受致死性甲型禽流感病毒(H5N1)感染。
Virology. 2017 Sep;509:90-97. doi: 10.1016/j.virol.2017.06.006. Epub 2017 Jun 16.
7
Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.含保守神经氨酸酶或 M2 胞外结构域表位嵌合血凝素缀合物的灭活重组流感病毒的交叉保护作用。
Virology. 2020 Nov;550:51-60. doi: 10.1016/j.virol.2020.08.003. Epub 2020 Aug 22.
8
Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.通用流感病毒神经氨酸酶疫苗可诱导针对人季节性和大流行前流感株的保护性免疫应答。
J Virol. 2021 Aug 10;95(17):e0075921. doi: 10.1128/JVI.00759-21.
9
Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.含有 B 细胞激活因子(BAFF)的高免疫原性流感病毒样颗粒,用于多亚型疫苗开发。
Antiviral Res. 2019 Apr;164:12-22. doi: 10.1016/j.antiviral.2019.02.004. Epub 2019 Feb 6.
10
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.用H5N1和甲型H1N1大流行性流感病毒的重组神经氨酸酶蛋白免疫引发的交叉反应性神经氨酸酶抑制抗体。
J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

引用本文的文献

1
Broad neuraminidase antibodies confer protection against seasonal and avian influenza viruses.广泛的神经氨酸酶抗体可提供针对季节性流感病毒和禽流感病毒的保护。
Nat Commun. 2025 Aug 2;16(1):7103. doi: 10.1038/s41467-025-62040-1.
2
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.基于病毒载体和病毒样颗粒的传染病疫苗:综述。
Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15.
3
A(H2N2) and A(H3N2) influenza pandemics elicited durable cross-reactive and protective antibodies against avian N2 neuraminidases.

本文引用的文献

1
Neuraminidase in Virus-like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection.病毒样颗粒中的神经氨酸酶有助于抵御高剂量禽流感病毒攻毒感染。
Pathogens. 2021 Oct 7;10(10):1291. doi: 10.3390/pathogens10101291.
2
Protective immunity induced by CpG ODN-adjuvanted virus-like particles containing Toxoplasma gondii proteins.含弓形虫蛋白的 CpG ODN 佐剂病毒样颗粒诱导的保护性免疫。
Parasite Immunol. 2021 Jan;43(1):e12799. doi: 10.1111/pim.12799. Epub 2020 Oct 26.
3
Influenza vaccine efficacy induced by orally administered recombinant baculoviruses.
A(H2N2) 和 A(H3N2) 流感大流行引发了针对禽 N2 神经氨酸酶的持久交叉反应性和保护性抗体。
Nat Commun. 2024 Jul 3;15(1):5593. doi: 10.1038/s41467-024-49884-9.
4
Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?呼吸道病毒及类病毒颗粒疫苗的研发:我们已经走了多远?
Viruses. 2023 Jan 30;15(2):392. doi: 10.3390/v15020392.
5
Platforms, advances, and technical challenges in virus-like particles-based vaccines.基于病毒样颗粒的疫苗的平台、进展和技术挑战。
Front Immunol. 2023 Feb 9;14:1123805. doi: 10.3389/fimmu.2023.1123805. eCollection 2023.
6
Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice.在小鼠中,用活流感病毒进行舌下接种比口服免疫诱导出更好的保护作用。
Life (Basel). 2022 Jun 29;12(7):975. doi: 10.3390/life12070975.
7
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses.含受体结合域的流感病毒样颗粒杂交疫苗可诱导针对流感病毒和新冠病毒的免疫反应。
Vaccines (Basel). 2022 Jun 14;10(6):944. doi: 10.3390/vaccines10060944.
口服重组杆状病毒诱导的流感疫苗效力。
PLoS One. 2020 May 27;15(5):e0233520. doi: 10.1371/journal.pone.0233520. eCollection 2020.
4
Factors That Govern the Induction of Long-Lived Antibody Responses.影响长效抗体应答诱导的因素。
Viruses. 2020 Jan 7;12(1):74. doi: 10.3390/v12010074.
5
Broadly protective human antibodies that target the active site of influenza virus neuraminidase.广谱保护性人源抗体靶向流感病毒神经氨酸酶的活性位点。
Science. 2019 Oct 25;366(6464):499-504. doi: 10.1126/science.aay0678.
6
Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.神经氨酸酶表达的病毒样颗粒疫苗为流感病毒提供了有效的交叉保护。
Virology. 2019 Sep;535:179-188. doi: 10.1016/j.virol.2019.07.008. Epub 2019 Jul 8.
7
Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs.流感 M2 病毒样颗粒疫苗接种与禽流感 HA VLPs 联合使用增强了保护作用。
PLoS One. 2019 Jun 27;14(6):e0216871. doi: 10.1371/journal.pone.0216871. eCollection 2019.
8
Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.通过接种经计算设计的流感病毒N1神经氨酸酶构建体来扩大对流感的免疫力。
NPJ Vaccines. 2018 Nov 29;3:55. doi: 10.1038/s41541-018-0093-1. eCollection 2018.
9
B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4 T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen.B 细胞是主要的抗原提呈细胞,在免疫接种病毒衍生的纳米颗粒抗原时,可激活初始 CD4 T 细胞。
Immunity. 2018 Oct 16;49(4):695-708.e4. doi: 10.1016/j.immuni.2018.08.012. Epub 2018 Oct 2.
10
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?神经氨酸酶为基础的免疫作用如何能有助于更好的流感病毒疫苗?
mBio. 2018 Apr 3;9(2):e02332-17. doi: 10.1128/mBio.02332-17.